“Non alcoholic fatty liver disease and eNOS dysfunction in humans” by unknown
RESEARCH ARTICLE Open Access
“Non alcoholic fatty liver disease and eNOS
dysfunction in humans”
Marcello Persico1* , Mario Masarone1, Antonio Damato2, Mariateresa Ambrosio2, Alessandro Federico3,
Valerio Rosato4, Tommaso Bucci1, Albino Carrizzo2 and Carmine Vecchione5
Abstract
Background: NAFLD is associated to Insulin Resistance (IR). IR is responsible for Endothelial Dysfunction (ED) through
the impairment of eNOS function. Although eNOS derangement has been demonstrated in experimental models, no
studies have directly shown that eNOS dysfunction is associated with NAFLD in humans. The aim of this study is to
investigate eNOS function in NAFLD patients.
Methods: Fifty-four NAFLD patients were consecutively enrolled. All patients underwent clinical and laboratory
evaluation and liver biopsy. Patients were divided into two groups by the presence of NAFL or NASH. We measured
vascular reactivity induced by patients’ platelets on isolated mice aorta rings. Immunoblot assays for platelet-derived
phosphorylated-eNOS (p-eNOS) and immunohistochemistry for hepatic p-eNOS have been performed to evaluate
eNOS function in platelets and liver specimens. Flow-mediated-dilation (FMD) was also performed. Data were
compared with healthy controls.
Results: Twenty-one (38, 8%) patients had NAFL and 33 (61, 7%) NASH. No differences were found between groups
and controls except for HOMA and insulin (p < 0.0001). Vascular reactivity demonstrated a reduced function induced
from NAFLD platelets as compared with controls (p < 0.001), associated with an impaired p-eNOS in both platelets and
liver (p < 0.001). NAFL showed a higher impairment of eNOS phosphorylation in comparison to NASH (p < 0.01).
In contrast with what observed in vitro, the vascular response by FMD was worse in NASH as compared with NAFL.
Conclusions: Our data showed, for the first time in humans, that NAFLD patients show a marked eNOS dysfunction,
which may contribute to a higher CV risk. eNOS dysfunction observed in platelets and liver tissue didn’t match
with FMD.
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Background
Non-Alcoholic Fatty Liver Disease (NAFLD) is repre-
sented by two clinical features: Non-Alcoholic Fatty Liver
(NAFL) (namely “steatosis”), and Non-Alcoholic-Steato-
Hepatitis (NASH) (namely: “steatohepatitis”). NAFLD is a
unique “challenge” for the hepatologists and has increased
worldwide in the last few years, due to the changes in diet-
ary habits and increased sedentary lifestyle. Consequently
NAFLD can be considered one of the most frequent liver
diseases in the world [1]. It is generally considered a
“benign disease” with low rates of progression to fibrosis,
cirrhosis and hepatocellular carcinoma (HCC) [2]. Never-
theless, because of the high number of affected patients,
the prevalence of related cirrhosis gradually increased, and
actually it represents the third cause of liver transplant-
ation in the USA. Moreover, even if the incidence of HCC
in NAFLD patients is lower than that in HCV/HBV cir-
rhotic patients, the absolute burden of NASH-related
HCC is higher, due to the higher number of patients with
NAFLD [3]. It is very likely that the importance of this
disease will continue to increase in the future, when the
new therapies and prevention programs for hepatitis C
and B will further reduce the size of viral infections of the
liver. For these reasons, to recognize the mechanisms
underlying its onset and progression is very important.
Even if a lot of insights on this topic have been postulated
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in the last few years, many aspects of the pathophysio-
logical mechanisms underlying this disease remain to be
explored. The hypothesis, risen from recent papers on
animal experimental models, that found a possible linkage
among microvascular abnormalities in the fatty liver, the
lipid accumulation into the hepatocytes, and the fibrosis
[4–6], seems to be of interest. In particular, it has been
postulated that in NAFLD may be present an endo-
thelial dysfunction that could be one of the earliest
factors associated to fat accumulation and liver dam-
age [7–9]. This finding is not totally surprising if we
consider that, since its discovery, NAFLD has been
widely associated to cardio-metabolic syndrome and
its components: hepatic and systemic insulin resist-
ance (IR), dyslipidemia, visceral obesity, hypertension,
impaired fasting glucose, [10] and increased stroke
risk [11]. Although a large number of insights on the
linkage between IR and liver damage are yet un-
known, what we know is that IR per se is responsible for
endothelial dysfunction, for example via the imbalance of
the enzymatic system of Nitric Oxide production (NO)
[12]. In fact, insulin was proven to induce endothelial
Nitric Oxide Synthase (eNOS) activation, resulting in
vasodilation and vascular protection [13]. When IR ap-
pears, it can also lead to endothelial dysfunction, through
the impairment of NO production and the inhibition of
insulin-induced vasorelaxation [14], and eNOS function
impairment has been widely associated to it [15].
Moreover, it was demonstrated that endothelial dys-
function with impaired NO production is involved in
the progression of advanced liver diseases such as
cirrhosis [16, 17], and it is associated with increased
vascular resistance (resulting in portal hypertension)
and hepatic stellate activation in the liver (resulting in
fibrosis) [18]. All together these evidence led to con-
sider the possibility, subsequently confirmed, that this
mechanism already acts in earlier stages of murine
experimental models of NAFLD-related liver damage
[7–9]. Nevertheless, to our knowledge, no experimen-
tal studies have confirmed these findings on human
models of NAFLD.
Flow-mediated vasodilation (FMD) of the brachial
artery by means of ultrasonography [19] is a well
known test to assess systemic endothelial function in
humans [20, 21] and its significant clinical value is
based on the assumption that the vasodilatory capacity
of a vessel during post-ischemic hyperemia depends on
a preserved NO synthesis and release [19]. In non-
cirrhotic subjects, cardiovascular risk factors impair
FMD due to the oxidative stress-induced systemic
endothelial dysfunction [22, 23].
The aim the of the present study is to try to demon-
strate that eNOS derangement together with FMD
impairment are associated with NAFLD.
Methods
Fifty-four consecutive patients (38 males, 16 females),
coming from January 2014 to April 2015 to our tertiary
center of Hepatology for the evaluation of their liver
disease by liver biopsy, were enrolled in the present
prospective case-control study. Inclusion criteria were
histological diagnosis of non alcoholic steatosis (NAFL)
and/or steatohepatitis (NASH). Exclusion criteria were
the presence of any other concomitant liver disease: viral
infections (HCV, HBV, HIV), autoimmunity, drug hepa-
titis, unsafe alcohol consumption (more than 20gr/day)
or neoplastic diseases. The control group consisted of
healthy volunteers matched for age and sex with the
study population was recruited by a local blood bank.
Patients were divided into two groups according to the
liver biopsy results: 1) simple steatosis (NAFL), 2) steato-
hepatitis (NASH). The results obtained in the individual
groups were compared between each other and with the
control group. NASH patients were also stratified by
fibrosis degree at liver biopsy.
Clinical evaluation: Of each patient (and control)
clinical history with alcohol consumption and smoking
habits registration, physical examination, arterial
pressure, waist circumference, body mass index (BMI),
blood glucose, total and fractioned cholesterol,
triglycerides, AST, ALT, GGT, ALP, complete
blood count, metabolic syndrome evaluation by
NCEP-ATPIII criteria were recorded [24].
Liver disease assessment: An abdomen ultrasound
examination with the evaluation of the liver echo
pattern of liver steatosis was performed by a skilled
ultrasonographist at the time of enrollment [25]. On
the basis of the clinical status of the patient and the
good clinical practice behaviour, liver tissue samples
were collected by performing a hepatic percutaneous
biopsy with Surecut 17G needles, via the intercostal
route using an echo-guided method. Liver specimens
were used for histological examination if they were at
least 1.5-cm long and contained >5 portal spaces.
Biopsies were evaluated by using both the Kleiner score
[26] for necroinflammation grading and fibrosis staging
and the Brunt score [27] for the presence and extent of
steatosis by a skilled pathologist. Each patient, and
control, was included in the study after signing a
written informed consent.
Ethics statement: The present study was approved by
our local ethical committees (Ethical Committee of
Istituto Neurologico Mediterraneo IRCCS Neuromed
for experimental animals and Ethical Committee
Campania Sud for patients and control subjects). The
study protocol is in accordance with the ethical
guidelines of the 1975 Declaration of Helsinki. All
animals received humane care according to the criteria
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outlined in the “Guide for the Care and Use of
Laboratory Animals” prepared by the National Academy
of Sciences and published by the National Institutes of
Health (NIH publication 86-23 revised 1985).
Evaluation of vasorelaxation activity inhibition
Platelet isolation and isolated vessel study: The assess-
ment of the eNOS function was performed by evaluating
vasorelaxation activity induced on isolated mice vessels
by platelet-rich plasma (PRP) obtained by peripheral
blood samples of patients and controls, activated with
insulin. The response to vasodilator supernatants obtained
through the stimulation of platelets with insulin was
examined after achieving a preconstricted tone with
increasing doses of phenylephrine on isolate mice aorta
rings. These were mounted between stainless steel triangles.
The whole method has been already described by our
group in a study on another patients’ setting [28].
Immunoblotting
After the isolation, platelets were solubilized in lysis
buffer. Then, the supernatants were used to perform im-
munoblot analysis with anti-phospho-eNOS S1177 (Cell
Signaling, rabbit polyclonal antibody 1:800); anti-total-
eNOS (Cell Signaling, mouse mAb 1:1000), anti-iNOS
(BD Laboratories cod.610599 mAb 1:800), anti-pAkt
(Thr 308, Santa Cruz sc-135650 mAb 1:800), anti-Akt
(Santa Cruz sc-56878 mAb 1:800) and β-actin (Cell
Signaling, mouse mAb 1:2000). The whole method has
been previously described [28].
Immunohistochemistry for hepatic eNOS
Sections of liver tissue were immunostained with p-eNOS
serin 1177 antibody (abcam ab75639). Briefly, 3-L thick
slices of formalin-fixed, paraffin-embedded liver were
mounted on slides. The slides were deparaffinized,
followed by suppression of endogenous peroxidase activity
by immersion in PBS containing 2% H2O2 for 30 min.
Nonspecific binding was blocked with 10% horse serum in
PBS at room temperature for 1 h. The sections were
washed in PBS with 0.05% Tween-20 thrice for 2 min each
time, followed by incubation overnight at 4 °C with mouse
anti-p-eNOS antibody [1:50] in PBS containing 4% horse
serum. The sections were washed in PBS twice for 2 min
each time, followed by incubation for 1 h at room
temperature with biotinylated goat anti-mouse IgG
[1:200] in PBS containing 1.5% horse serum. Then, the
slides were incubated with avidin-biotin peroxidase conju-
gate for 30 min at room temperature; the coloured reac-
tion product was developed by incubation for 7 min with
0.05% diaminobenzidine in 0.01% H2O2 in PBS. Negative
controls were carried out under the same conditions by
using mouse IgG instead of p-eNOS antibody.
FMD of brachial artery by ultrasound
FMD measurements were performed by a single oper-
ator trained in this method, holding an intra-observer
variability less than 5%. The technique was carried out
following the published guidelines [29]. In particular,
patients, after a fasting of at least 8 h, were examined
after a 20 min rest in a quiet and darkened room. They
were instructed of avoiding smoking, drinking coffee
and/or alcohol, and eating high-fatty food within the
previous 12 h. A standard cuff was positioned around
the right arm, 2 in. below the antecubital fossa, with the
patient in the supine position.
To acquire images of the right brachial artery, a 10-
MHz linear probe connected to a Hi Vision Preirus
ultrasound system (Hitachi Hi Vision Preirus, Hitachi
Medical Corporation, Tokyo, Japan) was used. Baseline
images were obtained for 2 min, then the right brachial
artery was occluded by inflating the cuff to above
250 mmHg, and kept inflated for 5 min. Subsequently,
the cuff was deflated and images of the right brachial
artery were captured. FMD was calculated with the fol-
lowing formula: (maximum diameter-baseline diameter)/
baseline diameter) × 100 [30].
Statistical analysis
Statistical analyses were performed by using the Statistical
Program for Social Sciences (SPSS®) ver.16.0 for Macintosh®
(SPSS Inc., Chicago, Illinois, USA). Student t-test and
Mann-Whitney U test were performed to compare
continuous variables, chi-square with Yates correction or
Fisher-exact test to compare categorical variables. Uni-
variate and multivariate analyses were performed to test
independent variables affecting the endothelial dysfunc-
tion, by performing ANOVA, linear regressions and
binary logistic regressions, where applicable. Statistical
significance was defined when “p < 0.05” in a “two-
tailed” test with a 95% Confidence Interval.
Sample size calculation: in order to find an adequate
sample size, we performed an interim analysis on the
first 18 patients (10 NASH and 8 NAFLD) and enrolled
controls, that we used as “calibration set”. The sample
size was calculated on the basis of the results of vasore-
laxation experiment. The number needed to elicit a
statistical difference between NAFL and NASH patients,
with a power of 0.9 and an alpha error of 0.01 in a two
sided test with 95% CI, was of 20 subjects per arm. We
decided to include all the 54 cases enrolled in the present
study to further improve the reliability of our results.
Results
Of the 54 patients 21 (38, 8%) had NAFL and 33 (61, 7%)
had NASH according to histological diagnosis. No statisti-
cally significant differences were found between the two
groups for age, sex, BMI, ALT, prevalence of hypertension,
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diabetes, dyslipidemia, obesity and metabolic syndrome.
The only statistical difference was found in HOMA score
and insulin levels (p < 0.001 both), see Table 1. Six patients
in NASH group at liver biopsy were found to have the
histological features of cirrhosis. Due to the fact that liver
cirrhosis may represent perse a cause of endothelial
derangement [31], we performed the vasoreactivity and
NOS evaluations with and without the samples derived
from cirrhotic patients, and we did not find any significant
difference in the results of the various experiments. The
data here presented belong to the non-cirrhotic patients.
Histological evaluation
As reported in methods, the diagnosis of NAFL or
NASH was performed by applying the Kleiner score to
the collected liver samples [26]. In particular, a patient
was defined to have NASH instead of simple NAFL if its
“NAFLD Activity Score” was ≥ 5, see Table 2.
Vasorelaxation induced by platelet-supernatant is altered
in steatosis/steatohepatitis
The supernatant from stimulated human platelets induced
a rapid dose-dependent relaxation of mice aorta rings and
was abolished by NOS inhibitor, L-NAME (data not
shown), clearly demonstrating the involvement of NO sig-
nalling in supernatant vascular action. Interestingly, our
data demonstrate that the vasorelaxant effect, induced
from platelet supernatants, was markedly reduced in
NASH/NAFL patients when compared to control subjects.
Moreover, the vasorelaxation induced from platelet super-
natants from NAFL patients was significantly reduced if
compared to that obtained from NASH subjects (Fig. 1).
Platelet eNOS-phosphorylation is impaired in steatosis/
steatohepatitis
Levels of eNOS phosphorylation (p-eNOS) decreased in
platelets of NASH patients compared to platelets of
control subjects. Interestingly, in platelets of NAFL
subjects there is an important impairment of eNOS
phosphorylation both versus control subjects and ver-
sus NASH patients. Conversely, eNOS expression did
not change among all the groups. In addition, no
changes in the levels of β-actin were observed between
all the groups, whereas levels of Akt phosphorylation
(pAkt) decreased as much as eNOS levels (Fig. 2).
These results reproduce and confirm those found on
vasorelaxation inhibitory mechanism (see Fig. 1).
To evaluate the involvement of iNOS in our results,
we performed its expression in our platelet samples. Our
data revealed an absence of iNOS expression in our
experimental conditions.
In agreement, It has been demonstrated that iNOS
expression is absent in platelets [32]. By contrast,
iNOS expression was enhanced after LPS treatment
in mice vessels (see Fig. 2), as previously demon-
strated [9].
eNOS phosphorylation is reduced in liver from steatosis/
steatohepatitis
Immunohistochemical data showed that liver samples
collected from health control subjects, showed a marked
staining for p-eNOS in S1177 compared to liver samples
obtained from both NASH and NAFL subjects. Interest-
ingly, the pattern of phosphorylated eNOS levels is
equivalent to that found, using western blot analyses, in
platelets from the same subjects (Fig. 3).




















BMI 22,91 ± 2,76 30,17 ± 3,86 <0.001 29,51 ± 3,31 30,6 ± 4,21 0.320
Hypertension 0 21 [38,9%] 0.005 7 [33,3%] 14 [42,4%] 0.521
Diabetes 0 11 [22,2%] 0.057 4 [19,0%] 7 [21,2%] 0.847
Dyslipidemia 0 35 [64,8%] <0.001 16 [76,2%] 19 [57,6%] 0.163
Obesity 3 [20,00%] 29 [53,7%] 0.021 12 [57,1%] 17 [51,5%] 0.686
Insulin – 17,65 ± 5,95 – 14,08 ± 2,06 21,18 ± 6,98 <0.001
HOMA – 4,36 ± 1,72 – 3,10 ± 0,08 5,24 ± 1,58 <0.001
Metabolic Syndrome 0 19 [35,2%] 0.007 7 [33,3%] 12 [36,4%] 0.820
Cirrhosis 0 6 [11,1%] 0.177 0 6 [18,2%] 0.077
ALT 26,44 ± 9,56 67,56 ± 44,37 <0.001 66,00 ± 43,65 68,33 ± 46,64 0.085
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Flow-mediated dilation (FMD) of the brachial artery by
ultrasound
FMD resulted lower, although not significant (p = 0.534),
in NAFL patients if compared to controls and
differed between NAFL and NASH, showing a statis-
tically significant FMD decrease (10.72 ± 0.89 vs 4.34
± 1.5 P <0.0001) in NASH patients (Fig. 4). This,
apparently, seems to contradict data reproduced by
platelet supernatant evoked vasorelaxation on mice
aorta rings (see Fig. 1) and possible interpretation of
discrepancy will be reported in discussion.
Discussion
The present study shows, for the first time in humans,
that an impaired eNOS function may be present in
NAFL and NASH. This could lead to a worse NO pro-
duction and an impairment of platelet-mediated vasore-
laxation induction. A novel “dynamic” method, already
proven to be an affordable and reliable tool to investi-
gate vascular and platelet eNOS function [33, 34], was
therefore used. Data here reported show that platelet-
mediated vasorelaxation effect is repressed in NAFL and
NASH patients. Since this effect is suppressed by NOS
inhibitors (i.e. L-NAME), it is clear that NO signalling is
involved in platelet-mediated vascular activity. This
novel approach may represent a reliable tool, available to
study the endothelial function in NAFLD patients. In
particular, it has the benefit of being substantially consti-
tuted by a simple blood sample analysis that can be
easily repeated, and might be easily used to assess the
course of the disease and/or the results of eventual
therapies.
The association between eNOS impairment and vascu-
lar reactivity seems to be related to the significantly
reduced functional fraction of eNOS, the Serine-1177
phosphorylated-eNOS, either in platelets derived by
peripheral blood samples and in liver tissue specimens
of NAFL and NASH patients, if compared to healthy
controls. This is in line with previous studies conducted
on murine experimental models of NAFL, in which e-NOS
dysfunction was also hypothesized [7, 8]. Thus, eNOS
derangement, leading to NO reduction and, conse-
quently, to endothelial dysfunction, might represent
one of the main pathophysiological mechanisms
involved in the liver damage by fat accumulation. In
this regard, recent studies, both in humans and animal
Fig. 1 Dose-response curves of phenylephrine-precontracted aorta rings to supernatants derived from stimulated platelets isolated from NASH,
Steatosis patients (“NAFL”) or Control subjects. Steatosis vs. controls:*, p < 0.05; **, p < 0.001; NASH vs. Steatosis: #, p < 0.05; ##, p < 0,001; NASH vs.
controls: ‡, p < 0.05
Table 2 Histological scores [mean ± SD] according to Kleiner score in NAFLD patients
Overall NAFL NASH p 95% CI
Steatosis [0–3] 1.8 ± 0.9 1.4 ± 0.7 2,1 ± 1.1 0.0122 −1.241/−0.159
Lobular Inflammation [0–2] 1.9 ± 1.0 0.9 ± 0.7 2.2 ± 1.2 0.0001 −1.881/−0.719
Hepatocellular Ballooning [0–2] 1.16 ± 0.7 0.7 ± 0.2 1.9 ± 1.1 0.0001 −1.688/−0.712










*NAFLD activity score: in parenthesis median and range
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models of NASH, demonstrated derangements in micro-
vascular functionality of the liver tissue [4, 5]. Moreover, a
sinusoidal dysfunction associated with lipid accumulation
in hepatocytes together with collagen deposition in the
space of Disse was also highlighted [5]. Furthermore, in
human liver specimens, iNOS expression, measured by
immunohistochemistry, was correlated to the histological
activity index and fibrosis in chronic viral hepatitis [35].
One of the main mechanisms promoting NO production
through the activation of eNOS is the insulin signaling
pathway [11, 12]. Insulin Resistance [IR], widely demon-
strated in NAFLD, might be the main trigger of eNOS
dysfunction that, therefore, might play a crucial role in the
onset of NAFLD. Liver sinusoidal endothelial cells act in
the same way of the other common endothelial cells. Their
function is crucial to defend the tissue from inflammation
and fibrosis [36, 37], therefore an impairment of their
activity may promote, or worsen, the inflammatory state,
known as “low-grade inflammation”, which underlies
NAFLD onset and progression [38]. This seems to be
supported by the fact that liver endothelial dysfunction is
significantly associated to advanced liver diseases (of every
etiology) and portal hypertension [39–41].
In this way, liver eNOS dysfunction might be one of
the earliest “triggers” of liver damage and an important
responsible for fibrosis progression.
It has been largely demonstrated in various experimen-
tal studies that the endothelial damage and derangement
of endothelial regulatory mechanisms represent the patho-
physiological basis of cardiovascular disease (CVD), and
probably, in this regard, eNOS and iNOS are the most
important elements. It is known that NAFLD may repre-
sent an independent risk factor for CVD as demonstrated
in several studies, also when adjusting for the “classical”
CVD risk factors, such as hypertension, dyslipidemia,
obesity, and diabetes [42–45]. Moreover, a wide variety of
Fig. 3 Immunohistochemistry of p-eNOS in the liver. Immunohistochemistry was performed on liver from three experimental condition: CTRL [control],
NASH and Steatosis (“NAFL”). Insets represent higher magnification micrographs of p-eNOS immunoreactivity
Fig. 2 Representative immunoblotting of eNOS phosphorylation at serine residue 1177 and Akt in threonine 308 in platelets and relative densitometric
analysis for p-eNOS (left panel), p-Akt (central panel) and eNOS (right panel)
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papers demonstrated that NAFLD is associated with in-
direct markers of microvascular dysfunction [46–49].
Here-reported eNOS dysfunction in NAFLD patients
might represent a significant contribution on the com-
prehension of the pathophysiological linkage between
NAFLD and CVD.
Another point raised by our results which deserves a
discussion is that the simple steatosis (NAFL), which
represents the early stage of the disease, seems to be
associated to a worse eNOS impairment compared to
steatohepatitis (NASH). This was confirmed both by the
dynamic evaluation on mice aorta rings, on which a
more intense inhibition of the vasorelaxation was found
in NAFL, and by Immunoblot assays, in which it was
clearly demonstrated that NAFL patients had signifi-
cantly lower levels of s1177-p-eNOS if compared to both
NASH and healthy controls. Finally, the immunohisto-
chemical evaluation of p-eNOS on the liver tissue sam-
ples confirmed this trend. On the other hand, clinical
evaluation of endothelial dysfunction, measured via
FMD, has shown to be worse in NASH than NAFL
patients, confirming a worse endothelial dysfunction
and, therefore, a higher risk of cardiovascular disease in
NASH subjects which has already been largely reported
[22, 23]. This apparent discrepancy between the con-
firmation of a higher cardiovascular risk derived from a
worse endothelial reactivity “in-vivo”, and a “less-worse”
eNOS function in NASH patients, is not explained by
any pharmacological influence that may have altered the
results. In fact, even if it is known that some drugs,
such as insulin sensitizer metformin [50–52], PPAR-
gamma agonists thiazoledinediones [53] calcium channel
blockers [54], ACE inhibitors and ARBs [55] may have a
positive effect on eNOS expression, no differences were
found in the use of these drugs between NAFL and NASH
patients in our population. Therefore, if we can reasonably
exclude any pharmacological interference, a plausible
hypothesis explaining our results might be represented by
the fact that, due to the worse insulin resistance, NASH
subjects have a higher circulating insulin level if compared
to NAFL patients, as demonstrated by insulin levels and
HOMA scores (see Table 1). This “hyper-insulinemia”
could lead to a “partial recovery” of the eNOS phosphoryl-
ation which, in turn, may explain the slightly better eNOS
activity of NASH patients compared to NAFL ones. Inter-
estingly, this last hypothesis is supported by our finding
showing that Akt impairment is more evident in NAFL as
compared to NASH. Another possible speculation could
concern the fact that in a chronic disease such as NASH,
a large amount of cytokines are released. Some of them
(ie. VEGF, TNF-alpha and TGF-beta) were proven to have
effects on eNOS expression and activity [55]. In such a
“signaling storm” a mechanism of positive feedback could
be postulated, and lead to a partial recovery of eNOS
phosphorylation. Moreover, it has to be pointed out that
not even the histological finding of a cirrhosis influenced
these results: even if we presented the data without the six
NASH patients with histological diagnosis of fibrosis, we
carried out also the experiments including these samples,
and nothing changed in terms of statistical significance.
Finally, the discrepancy between clinical and laboratory
results may also be explained by the higher redox status in
NASH. In fact, the presence of inflammatory status leads
to ROS production that reduces both bioavailability and
NO production. In particular, superoxide anion (O2-) can
blind NO, producing peroxynitrite (ONOO-), an highly
toxic reactive oxygen species, and can interact with tetra-
hydro-bio-pterin determining the decoupling of eNOS.
These speculative interpretations need to be warranted by
further studies, currently performed in our lab. However,
the mechanisms underlying the endothelial dysfunction,
here reported, support the idea that the endothelial dys-
function might play a crucial role in the pathological “first
hit”, responsible for fat accumulation in NAFLD, appar-
ently dissociated by the following chronic inflammatory
process that per se might beresponsible for the evolution,
through fibrosis, to more severe steatohepatitis. Sophisti-
cated and intriguing hypotheses of pathophysiological
mechanism (s) modifying the endothelial function in
NAFL and NASH patients represent the main message of
the present study NASH patients have a higher cardiovas-
cular risk, as documented by FMD measurements.
Study limitations
The present study has some limitations. Firstly, the
present data need to be validated on larger series.
Then, it is already well known that vascular dysfunc-
tion involves not only eNOS, but also the inducible iso-
form of Nitric Oxyde Synthase (iNOS) which was not
present in the human platelets evaluated, and it may be
Fig. 4 Flow-mediated dilation evaluation of patients and controls in
our study population
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investigated in future studies using another experimen-
tal model. Finally, these data should be investigated
together with the evaluation of direct markers of liver
inflammation and fibrosis (such as TNF-alpha, TGF-
beta and collagenase) in order to find any supposed
direct correlation between endothelial dysfunction and
liver disease progression.
Conclusions
Data here reported support the idea that IR-associated
eNOS dysfunction may represent a peculiar and essential
mechanism of liver damage in NAFLD, that might also
represent a pathological linkage between NAFLD and
CVD. Moreover, supporting the pathogenic hypothesis of
“multiple parallel hits”, data here reported seem to dem-
onstrate that eNOS dysfunction might be regarded as an
essential pathophysiological feature of the “first hits” of
the chronic progressive process of NAFLD/NASH.
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